# VOLUME 22 1985

## SUBJECT INDEX


Acetylcholinesterase, 961
  baboons
  discrimination
  soman
Acquisition, 1061
  drug interaction
  monkeys
  opioids
Activity, 107
  lead exposure
  stress
Acute intoxication, 811
  alcohol metabolism
  body composition
  human studies
Adenosine receptors, 195
  caffeine
  methyl xanthines
  taste
Adrenal responses, 357
  drug interaction
  ethanol dependence
Adrenergic stimulation, 613
  drug interaction
  lordosis
  molecular regulation
α-Adrenergic antagonists, 279
  beta adrenergic antagonists
  lordosis
  progesterone
β-Adrenergic antagonists
  α-adrenergic antagonists, 279
  drinking, 553
  lordosis, 279
  progesterone, 279
  thirst, 553
  water deprivation, 553
α-Adrenergic receptors, 859
  [$^3$H]prazosine
  [$^3$H]WB4101
  receptor autoradiography
α-2 Adrenergic receptors, 835
  receptor subtypes
  strain differences
β-Adrenergic receptors, 711
  audiogenic seizures
  epilepsy
Adrenoceptors, 875
  electrophysiology
  neuropharmacology
  single unit studies
$\alpha_1$-Adrenoceptors, 827
  $\alpha_2$-adrenoceptors
  cardiovascular system
$\alpha_2$-Adrenoceptors, 827
  $\alpha_1$-adrenoceptors
  cardiovascular system
Age differences, 301
  learning
  memory
  radial maze performance
  spatial discrimination task
Aggression, 135
  d-amphetamine
  monkeys
  social interaction
Aging
  clonidine, 1075
  denervation, 1075
  dopamine, 461
  6-hydroxydopamine, 1075
  locomotor activity, 461, 1071
  nialamide, 461
Alcohol, 233
  human studies
  luteinizing hormone levels
  menopausal women
Alcohol metabolism, 811
  acute intoxication
  body composition
  human studies
Alcoholism, 483
  conditioned place preference
  ethanol reinforcement
Aldosterone, 707
  body fat
  body water
  skeletal growth
Alloxan, 407
  2-deoxy-D-glucose
  glucoprivic feeding
  5-thioglucose
Aminoacidura, 1053
  hyperprolinemia
  learning deficits
  proline
Amitriptyline, 119
  energy balance
  glucoregulation
  lithium
  mianserin
Amnesia, 377
  brain serotonin
  memory
Amphetamine
  anorexia, 57
  desmethylimipramine, 57
  DRL-20, 1001
  intracranial drug administration, 57
  lesions, cortical, 1001
  morphine, 101
  neuroleptics, 101
  place conditioning, 101
  reward, 101
  supersensitivity, 1001
d-Amphetamine
  aggression, 135
  biogenic amine, 127
  drug interactions, 127
  fenfluramine, 127
  monkeys, 135
  social interaction, 135
Amphetamine reinforcement, 169
  conditioned place preference
  ethanol reinforcement
Analgesia
  cold water swim, 769
  naltrexone, 769
  pain modulation, 845
  spinal adrenergic receptors, 845
  spinopetal pathways, 845
  stress, 769
  tolerance, 769
Analgesic mechanisms, 47
  anxiolytic effects
  diazepam
  drug interactions
Anhedonia, 787
  neuroleptics
  pimozide
  reward
  sham feeding
Animal models, 383
  anxiolytic tolerance
  benzodiazepines
  defensive burying
Aniracetam
  avoidance, 645
  locomotor activity, 645
  matching-to-sample, 745
  monkeys, 745
  pigeons, 745
  piracetam, 645
  short-term memory, 745
Anorexia
  amphetamine, 57
  cyclazocine, 671
  desmethylimipramine, 57
  eating, 671
  intracranial drug administration, 57
  locomotor activity, 671
  quipazine, 671
Anticonvulsants
  drug interactions, 53
  eboracin, 53
  GABAergic mechanisms, 141
  pentobarbital, 141
  phenytoin, 53
  seizures, maximal electroshock induced, 141
Antidepressants
  benzodiazepine antagonists, 71
  conditioned avoidance, 261
  norepinephrine uptake, 261
  psychotropic drugs, 71
  shuttle box, 71
Antihistamines
  drug interactions, 469
  drug toxicity, 469
  nicotine, 469
  pentylenetetrazole, 469
  sedation, 15
  stimulus control, 15
Antinociception
  baclofen, 905
  benzodiazepine receptor binding, 1007
  clonidine, 905
  dopamine antagonists, 905
  hippocampus, 1007
  methylxanthines, 905
  triethyl lead, 1007

Anxiety, 941
β-carbolines
exploration
FG 7142
locomotor activity
plasma concentrations
social interaction
Anxiolytic effects, 47
analgesic mechanisms
diazepam
drug interactions
Anxiolytic tolerance, 383
animal models
benzodiazepines
defensive burying
Apomorphine
denervation supersensitivity, 547
dopamine receptors, 577
drug discrimination, 179, 577
drug interaction, 179, 209
ethanol, 179
lesions, 6-hydroxydopamine, 547
opiates, 209
pigeons, 209
Apparatus
osmotic mini pump, 897
Appetite
clonidine, 649
drinking, 699
eating, 649, 699
film autoradiography, 699
gustatory neuroanatomy, 699
rabbits, 649
stereospecific opiate antagonism, 649
taste preference, 699
Asymmetry, 327
serotonin concentrations
spontaneous activity
Atropine, 243
caudate nucleus
passive avoidance
memory
retention
striatal cholinergic activity
Audiogenic seizures
β-adrenergic receptors, 711
betaine, 635
epilepsy, 711
pentylenetetrazol, 635
seizures, 635
Aversion, 695
avoidance
exploration
lithium
position learning
Avoidance
aniracetam, 645
aversion, 695
exploration, 695
freezing behavior, 435
lithium, 695
locomotor activity, 645
pentobarbital, 435
piracetam, 645
position learning, 695
strain differences, 435

Baboons
acetylcholinesterase, 961
discrimination, 583, 961
ethanol, 583
soman, 961
toluene, 583
Baclofen, 905
antinociception
clonidine
dopamine antagonists
methylxanthines
Barbiturates, 955
dependence
sodium transport
tolerance
Behavioral development, 441
motor activity
naltrexone
opiate antagonists
Behavioral inhibition, 25
diazepam
locomotor activity
Benzodiazepine antagonists, 71
antidepressants
psychotropic drugs
shuttlebox
Benzodiazepine receptor binding, 1007
antinociception
hippocampus
triethyl lead
Benzodiazepine receptors, 985
cerebellum
cortex
receptor ontogeny
Benzodiazepines, 383
animal models
anxiolytic tolerance
defensive burying
Betaine
audiogenic seizures, 635
dimethylglycine, 641
pentylenetetrazol, 635
sarcosine, 641
seizures, 635, 641
strychnine, 641
Biogenic amine
d-amphetamine, 127
catecholamine analysis, 85
drug interactions, 127
fenfluramine, 127
HPLC, 85
Body composition, 811
acute intoxication
alcohol metabolism
human studies
Body fat, 707
aldosterone
body water
skeletal growth
Body temperature
brain AChE activity, 623
diisopropylfluorophosphate, 623
ethanol, 973
heart rate, 973
strain differences, 623
tolerance, 973
Body water, 707
aldosterone
body fat
skeletal growth
Body weight, 1071
food delivery schedule
food deprivation
phentermine
self-administration
Bombesin, 893
cholecystokinin
operant responding
satiety
Brain
amygdala, 859
caudate nucleus, 159, 183, 243
central nervous system, 19, 619
cerebellar Purkinje neurons, 875
cerebellum, 297, 985
cerebral cortex, 221, 301, 327
corpus striatum, 77
cortex, 985
dentate gyrus, 449
dorsal raphe nucleus, 859, 875
forebrain, 859
frontal neocortex, 531
hippocampus, 147, 183, 297, 449, 1007
hypothalamus, 77, 127, 175, 859
hypothalamus-preoptic area, 227
lateral geniculate nucleus, 875
locus coeruleus, 859
median raphe, 327
medial septum, 309, 449
nigro-striatal dopamine tract, 547
nucleus accumbens, 461
nucleus locus coeruleus, 875
parabrachial nucleus, 859
paraventricular nucleus, 1045
pons-medulla, 127
preoptic-anterior hypothalamus, 337
prepyriform cortex, 421
spinal cord, 221
striatum, 205, 689
substantia nigra, 127, 521
thalamus, 127
ventromedial hypothalamus, 535, 589
Brain AChE activity, 623
body temperature
diisopropylfluorophosphate
strain differences
Brain serotonin
amnesia, 377
p-chloroamphetamine, 889
memory, 377
rapid eye movement, 889
respiratory rate, 889
Brain stimulation reward, 527
self-stimulation threshold
Brown adipose tissue, 781
caffeine
drug synergism
dl-phenylpropanolamine
thermogenesis

Cadmium, 619
central nervous system
depression
drug interaction
Caffeine
adenosine receptors, 195
brown adipose tissue, 781
2-chloroadenosine, 421
drug interaction, 421
drug synergism, 781
haloperidol, 421
hippocampus, 449
hyperactivity, 449
juvenile rats, 421
locomotor activity, 421
L-PIA, 449
methyl xanthines, 195
operant behavior, 449
dl-phenylpropanolamine, 781
taste, 195
thermogenesis, 781
β-Carbolines, 941
anxiety
exploration
FG 7142

locomotor activity
plasma concentrations
social interaction
Cardiovascular system, 827
$\alpha_1$-adrenoceptors
$\alpha_2$-adrenoceptors
Castration effects, 1019
drug interaction
neonatal exposure
pituitary function
Catecholamine analysis, 85
biogenic amines
HPLC
Catecholaminergic drugs, 403
drug interaction
exploratory behavior
habituation
Cathinone, 913
cocaine
drug discrimination
methamphetamine
stimulus properties
Caudate nucleus
atropine, 243
locomotor activity, 159
memory, 243
passive avoidance, 243
$\beta$-phenylethylamine, 159
retention, 243
striatal cholinergic activity, 243
Central nervous system, 619
cadmium
depression
drug interaction
Cerebellum, 985
benzodiazepine receptors
cortex
receptor ontogeny
CGS 9896, 753
clonazepam
eating
hyperphagia
Ro5-3663
Ro5-4864
Ro15-1788
Chlordiazepoxide, 665
emotional responsiveness
locomotor activity
stress
2-Chloroadenosine, 421
caffeine
drug interaction
haloperidol
juvenile rats
locomotor activity
*p*-Chloroamphetamine, 889
brain serotonin
rapid eye movement
respiratory rate
Cholecystokinin, 893
bombesin
operant responding
satiety
Cholinesterase, 479
extrapyramidal system
stereotypy
motor activity
Chronic drug treatment, 283
muscarinic receptors
nicotine
oxotremorine
tolerance
Classical conditioning, 41
LSD
morphine
nictitating membrane response
rabbits
Clonazepam, 753
CGS 9896
eating
hyperphagia
Ro5-3663
Ro5-4864
Ro15-1788
Clonidine
aging, 1075
antinociception, 905
appetite, 649
baclofen, 905
cross-tolerance, 573
denervation, 1075
dopamine antagonists, 905
eating, 649
fixed ratio schedules, 573
6-hydroxydopamine, 1075
locomotor activity, 1075
methylxanthines, 905
morphine, 573
rabbits, 649
social play, 881
stereospecific opiate antagonism, 649
yohimbine, 881
CNS stimulants, 723
drug discrimination
hallucinogens
phenylisopropylamines
structure-activity studies
Cocaine
cathinone, 913
conditioned taste aversion, 945
dopamine, 945
drug discrimination, 913
kindling, 421
methamphetamine, 913
prepyriform cortex, 421
rotational behavior, 901
self-administration, 945
sensitization, 901
stimulus properties, 913
tolerance, 901
Cold water swim, 769
analgesia
naltrexone
stress
tolerance
Colonic temperature, 337
handling stress
hyperthermic
naltrexone
Concurrent, 61
fixed ratio schedule
monkeys
nicotine
self administration
Conditioned avoidance, 261
antidepressants
norepinephrine uptake
Conditioned place preference
alcoholism, 483
amphetamine reinforcement, 169
ethanol reinforcement, 169, 483
nicotine, 237
Conditioned taste aversion
cocaine, 945
dopamine, 945
opiate-ethanol interaction, 255
receptor stereospecificity, 255
self-administration, 945
Conditioned preference, 1045
eating
norepinephrine
quinine aversion
saccharin preference
Conditioned suppression, 249
electric footshock
motility
opioid activity
pain-threshold
Copulation, 1
fluprazine
sexual behavior, male rats
Cortex
benzodiazepine receptors, 985
cerebellum, 985
glutamate, 531
helplessness, 531
receptor ontogeny, 985
stress, 531
Cross-tolerance, 573
clonidine
fixed ratio schedules
morphine
Cyclazocine
anorexia, 671
eating, 671
locomotor activity, 671
pentylenetetrazol seizures, 515
quipazine, 671
rabbits, 515
Cyclic AMP
habituation, 631
learning, 183
pituitary, 631
stress, 631
vasopressin, 183

Defensive burying, 383
animal models
anxiolytic tolerance
benzodiazepines
Denervation, 1075
aging
clonidine
6-hydroxydopamine
locomotor activity
Denervation supersensitivity, 547
apomorphine
lesions, 6-hydroxydopamine
2-Deoxy-D-glucose, 407
alloxan
glucoprivic feeding
5-thioglucose
Dependence
barbiturates, 955
ethanol consumption, 19
indomethacin, 921
initial sensitivity, 19
morphine, 921, 933
operant behavior, 921, 933
prostaglandins, 921, 933
sodium transport, 955
tolerance, 921, 955
Depletion, 153
monoamine
phenol-induced tremor
Depression, 619
cadmium
central nervous system
drug interaction
Desipramine, 917
hyperactivity
hypoactivity
locomotor activity

Desmethylimipramine, 57
amphetamine
anorexia
intracranial drug administration
Diazepam
analgesic mechanisms, 47
anxiolytic effects, 47
behavioral inhibition, 25
drug interactions, 47
locomotor activity, 25
Diet, 993
ethanol
human studies
social drinking
urinary salsolinol
Diisopropylfluorophosphate, 623
body temperature
brain AChE activity
strain differences
Dimethylglycine, 641
betaine
sarcosine
seizures
strychnine
Discrimination
acetylcholinesterase, 961
baboons, 583, 961
ethanol, 583
head-dipping, 521
pimozide, 521
reward, 521
self-stimulation, 521
soman, 961
toluene, 583
Discrimination avoidance, 717
olfactory bulbectomy
psychotropic drugs
DL-erythro-DOPS, 979
DL-threo-DOPS
locomotor activity
DL-threo-DOPS, 979
DL-erythro-DOPS
locomotor activity
Dopamine
aging, 461
cocaine, 945
conditioned taste aversion, 945
enkephalin, 599
estrogen, 689
locomotor activity, 461, 599
motility, 599
nialamide, 461
ovariectomy, 689
postural deviation, 689
self-administration, 945
Dopamine antagonists
antinociception, 905
baclofen, 905
clonidine, 905
dopamine agonists, 309
methylxanthines, 905
3-PPP, 309
self-stimulation, 309
Dopamine depletion, 737
methamphetamine
rhesus monkeys
supersensitivity
tolerance
Dopamine-β-hydroxylase inhibitors, 535
eating
locomotor activity
norepinephrine
Dopamine receptors
apomorphine, 577
drug discrimination, 577
locomotor activity, 341
rearing, 341
Dopamine uptake, 731
phencyclidine
$^3$H-phencyclidine binding
turning behavior
Dopaminergic pathways, 31
penile erections
yawning
Dorsal immobility response, 505
morphine
naloxone
tonic immobility
Drinking
β-adrenergic antagonists, 553
appetite, 699
ethanol, 493
film autoradiography, 699
gustatory neuroanatomy, 699
hypertonic saline, 493
taste preference, 699
thirst, 493, 553
water deprivation, 553
DRL-20, 1001
amphetamine
lesions, cortical
supersensitivity
Drug
acetylcholine, 509
adenosine, 195
alaproclate, 5
alcohol, 233, 811
N-allylnormetazocine, 731
amineptine, 71
aminooxyacetic acid, 77
amitriptyline, 119, 261, 717
amphetamine, 57, 101, 169, 421, 599, 723, 1001
d-amphetamine, 127, 135, 309
anhendonia, 661
aniracetam, 645, 745
apomorphine, 31, 179, 209, 309, 403, 547, 577, 665, 737
atenolol, 553
atropine, 243
azatidine, 15
baclofen, 905
betaine, 635, 641
bicuculline, 77
bromocryptine, 31
butoxamine, 553
cadmium, 619
caffeine, 195, 421, 449, 815
β-carbolines, 941
cathinone, 913
β-CCM, 71
CGS 7525A, 71
CGS 8216, 71
CGS 9896, 753
chlordiazepoxide, 665, 717, 815
chlorimipramine, 261
2-chloroadenosine, 421
p-chloroamphetamine, 889
chlorpheniramine, 15
chlorpromazine, 541, 717
cholinesterase, 479
cinanserin, 5
clomipramine, 205
clonazepam, 753
clonidine, 403, 613, 649, 665, 854, 881, 905, 1075
clozapine, 541
cocaine, 61, 421, 901, 913, 945
colchicine, 449
cyclazocine, 515, 671, 731, 1061
l-desamino-8-D-arginine vasopressin, 183
desipramine, 183, 261, 917
desmethylimipramine, 57, 327
dextran, 493
dextrorphan, 255
diazepam, 25, 47, 141, 383
diethylstilbestrol, 1019
5,7-dihydroxytryptamine, 221, 327, 1013
diisopropylfluorophosphate, 623
N,N dimethylglycine, 641
diphenhydramine, 15, 333, 469
dopamine, 209, 357, 461, 509, 577, 661, 665, 689, 945, 979
DRL-20, 1001
eboracin, 53
epinephrine, 357
ethanol, 19, 91, 141, 169, 179, 255, 293, 357, 483, 493, 583, 797, 973, 993, 1013
ethylcholine ayiridinium chloride, 297
ethylketocyclazocine, 731
etoxadrol, 731
fenfluramine, 127, 377
FG 7142, 941
FLA-63, 535
$^3$H-flunitrazepam, 985
fluoxetine, 261, 377
α-flupenthixol, 101, 761
fluprazine hydrochloride, 1
fusaric acid, 535
glutamate, 531
glycine betaine, 641
haloperidol, 101, 265, 309, 403, 421, 509, 541, 661, 737
halothane, 797
heroin, 175, 215, 1061
hexamethonium, 237
B-HT 920, 403
5HTP, 5
6-hydroxydopamine, 901, 1013, 1075
5-hydroxyindoleacetic acid, 371, 683
5-hydroxytryptamine, 683
imipramine, 261, 377, 531
indomethacin, 921
isobutylmethylxanthine, 905
isoproterenol, 613
ketamine, 653, 731
ketanserin, 5, 565
lead, 107
levorphanol, 255
lidocaine, 421
lisuride, 677
LSD, 41
lithium, 119, 559, 695
maprotiline, 261
mecamylamine hydrochloride, 237
metallothionine, 619
metergoline, 5, 265, 421
methadone, 949, 1061
methamphetamine, 717, 737, 913
5-methoxy-N,N-dimethyltryptamine, 489
methimazole, 605
methylphenidate, 479, 509
α-methyl-p-tyrosine, 403
methylxanthine, 195, 815, 905
methysergide, 5, 885, 1025
metoclopramide, 31
mianserin, 5, 119
molidone, 309
monoamine oxidase, 461
morphine, 41, 101, 157, 227, 255, 271, 333, 361, 395, 505, 535, 921, 933, 949

naloxone, 37, 47, 91, 209, 361, 505, 509, 515, 599, 791, 933, 1035
naltrexone, 175, 337, 399, 441, 649, 769, 1035, 1061
nialamide, 461
nicotine, 61, 237, 283, 897
nicotine tartrate, 469
nomifensine, 71, 309
noradrenaline, 183, 979
norepinephrine, 357, 535, 613, 665
nortriptyline, 261
6-OHDA, 183
8-OH-PPAT, 489
oxaprotiline, 261
oxotremorine, 283
pargyline, 221
pentazocine, 333
pentobarbital, 141, 365, 435, 619
pentylenetetrazol, 53, 71, 469, 515, 635
peribedil, 577
phencyclidine, 731, 1061
phenethylamine, 497
phenobarbital, 389, 955
phenoxybenzamine, 279
phentermine, 1071
phentolamine, 57, 265
β-phenylethylamine, 159
phenylpiperzine, 1
dl-phenylpropanolamine, 781
phenytoin, 53, 389
physostigmine, 479
L-PIA, 449
picrotoxin, 141
pimozide, 521, 599, 787, 945
pindolol, 711
piracetam, 645
pirenperone, 565, 677
prazosin, 279, 421, 613, 835, 845
[$^3$H]prazosin, 859
progabide, 141
promethazine, 15
propranolol, 279, 421, 553, 613, 711
d,l propranolol, 553
prostaglandin, $D_2$, 365, 371
protriptyline, 261
quinine, 1045
quipazine, 5, 265, 489, 565, 665, 671, 677, 885, 1025
reserpine, 153
Ro5-3663, 753
Ro5-4864, 753
Ro15-1788, 71, 141, 753
Ro-44602, 221
rubidium, 559
sarcosine, 641
SCH 23390, 341
scopolamine, 745
serotonin, 5, 205, 265, 565, 665, 979
SKF 38393, 577
sodium pentobarbital, 395
soman, 961
strychnine, 619, 641
sulfonyl fluorides, 479
tetrabenazine, 153
Δ$^9$-tetrahydrocannabinol, 343, 415
theobromine, 195
theophylline, 195, 815, 905
toluene, 583, 797
tranylcypromine, 377
trazodone, 347
triethyl lead, 1007
trimethyl tin, 147
tripelennamine, 333, 469
tryptophan, 371
valproic acid, 389
viloxazine, 71
[$^3$H]WB4101, 859
yohimbine, 403, 421, 835, 845, 881
zimelidine, 5
Drug discrimination
  apomorphine, 179, 577
  cathinone, 913
  CNS stimulants, 723
  cocaine, 913
  dopamine receptors, 577
  drug interaction, 179
  ethanol, 179
  hallucinogens, 723
  methamphetamine, 913
  methylxanthine, 815
  operant behavior, 815
  phenylisopropylamines, 723
  phosphodiesterase inhibitor, 815
  stimulus properties, 913
  structure-activity studies, 723
Drug interaction
  acquisition, 1061
  adrenal responses, 357
  adrenergic stimulation, 613
  d-amphetamine, 127
  analgesic mechanisms, 47
  anticonvulsants, 53
  antihistamines, 469
  apomorphine, 179, 209
  anxiolytic mechanisms, 47
  biogenic amine, 127
  cadmium, 619
  caffeine, 421
  castration effects, 1019
  catecholaminergic drugs, 403
  central nervous system, 619
  2-chloradenosine, 421
  depression, 619
  diazepam, 47
  drug discrimination, 179
  drug interaction, 179
  drug toxicity, 469
  eboracin, 53
  ethanol dependence, 357
  exploratory behavior, 403
  fenfluramine, 127
  habituation, 403
  haloperidol, 421
  juvenile rats, 421
  locomotor activity, 421
  lordosis, 613
  molecular regulation, 613
  monkeys, 1061
  morphine analgesia, 395
  neonatal exposure, 1019
  nicotine, 469
  opiates, 209
  opioids, 1061
  pentobarbital, 395
  pentylenetetrazole, 469
  phenytoin, 53
  pigeons, 209
  pituitary function, 1019
  potentiation, 395
Drug synergism, 781
  brown adipose tissue
  caffeine
  dl-phenylpropanolamine
  thermogenesis
Drug toxicity, 469
  antihistamines
  drug interactions
  nicotine
  pentylenetetrazole
Eating
  anorexia, 671
  appetite, 649, 699
  CGS 9896, 753
  clonazepam, 753
  clonidine, 649
  conditioned preference, 1045
  cyclazocine, 671
  dopamine-β-hydroxylase inhibitors, 535
  film autoradiography, 699
  gustatory neuroanatomy, 699
  hyperphagia, 753
  locomotor activity, 535, 671
  norepinephrine, 535, 1045
  quipazine, 671
  quinine aversion, 1045
  rabbits, 649
  Ro5-3663, 753
  Ro5-4864, 753
  Ro15-1788, 753
  saccharin preference, 1045
  stereospecific opiate antagonism, 649
  taste preference, 699
Eboracin, 53
  anticonvulsants
  drug interactions
  phenytoin
Electric footshock, 249
  conditioned suppression
  motility
  opioid activity
  pain-threshold
Electroconvulsive shock, 683
  head twitches
  locomotor activity
Electrophysiology, 875
  adrenoceptors
  neuropharmacology
  single unit studies
Emotional responsiveness, 665
  chlordiazepoxide
  locomotor activity
  stress
Endogenous opiates, 91
  ethanol
  naloxone
  self-administration
Endorphins, 791
  naloxone
  opiate abstinence syndrome
  opiate antagonists
Energy balance, 119
  amitriptyline
  glucoregulation
  lithium
  mianserin
Enkephalin, 599
  dopamine
  locomotor activity
  motility
Epilepsy, 711
  β-adrenergic receptors
  audiogenic seizures
  Estrogen
Estrogen, 689
  dopamine
  ovariectomy
  postural deviation
Ethanol
  apomorphine, 179
  baboons, 583
  body temperature, 973
  diet, 993
  discrimination, 583

drinking, 493
drug discrimination, 179
drug interaction, 179
endogenous opiates, 91
halothane, 797
heart rate, 973
human studies, 993
hypertonic saline, 493
learned tolerance, 293
locomotor activity, 1013
monoamine content, 1013
naloxone, 91
operant behavior, 797
self-administration, 91
social drinking, 993
solvents, 797
tail flick, 293
thirst, 493
thyrotropin-releasing hormone, 1013
tolerance, 973
toluene, 583, 797
urinary salsolinol, 993
Ethanol, acute, 77
ethanol, chronic
GABA mediated mechanisms
tolerance
Ethanol, chronic, 77
ethanol, acute
GABA mediated mechanisms
tolerance
Ethanol consumption, 19
dependence
initial sensitivity
Ethanol dependence, 357
adrenal responses
drug interaction
Ethanol reinforcement
alcoholism, 483
amphetamine reinforcement, 169
conditioned place preference, 169, 483
Ethanol, voluntary intake, 205
serotonin
striatum
Ethylcholine aziridinium, 297
high affinity choline uptake
passive avoidance
Excretion, 497
phenethylamine
stress
Exocrine pancreas, 589
intestinal enzyme activity
linear growth
obesity
synthetic diets
Exploration
anxiety, 941
aversion, 695
avoidance, 695
β-carbolines, 941
FG 7142, 941
lithium, 695
locomotor activity, 941
plasma concentrations, 941
position learning, 695
social interaction, 941
Exploratory behavior, 403
catecholaminergic drugs
drug interaction
habituation
Extinction, 661
haloperidol
neuroleptics
reinforcement
Extrapyramidal system, 479
cholinesterase
stereotypy
motor activity

Female receptivity, 5
5HT receptor blockers
5HT synthesis
lordosis
Fenfluramine, 127
d-amphetamine
biogenic amine
drug interactions
FG 7142, 941
anxiety
β-carbolines
exploration
locomotor activity
plasma concentrations
social interaction
Film autoradiography, 699
appetite
drinking
eating
gustatory neuroanatomy
taste preference
Fixed ratio schedule
clonidine, 573
concurrent, 61
cross-tolerance, 573
monkeys, 61
morphine, 573
nicotine, 61
phenobarbital, 389
phenytoin, 389
self administration, 61
valproic acid, 389
Fluprazine, 1
copulation
sexual behavior, male rats
Food delivery schedule, 1071
body weight
food deprivation
phentermine
self-administration
Food deprivation, 1071
body weight
food delivery schedule
phentermine
self-administration

GABA mediated mechanisms, 77
ethanol, acute
ethanol, chronic
tolerance
GABAergic mechanisms, 141
anticonvulsants
pentobarbital
seizures, maximal electroshock induced
Genetics, 415
sexual behavior, male mice
$\Delta^9$-tetrahydrocannabinol
Glucoprivic feeding, 407
alloxan
2-deoxy-D-glucose
5-thioglucose
Glucoregulation, 119
amitriptyline
energy balance
lithium
mianserin
Glutamate, 531
cortex
helplessness
stress
Gustatory neuroanatomy, 699
appetite
drinking
eating
film autoradiography
taste preference

Habituation
catecholaminergic drugs, 403
cyclic AMP, 631
drug interaction, 403
exploratory behavior, 403
pituitary, 631
stress, 631
Hallucinogens
CNS stimulants, 723
drug discrimination, 723
5HT receptors, 677
operant behavior, 677
phenylisopropylamines, 723
pirenperone, 677
structure-activity studies, 723
Haloperidol
caffeine, 421
2-chloroadenosine, 421
drug interaction, 421
extinction, 661
juvenile rats, 421
locomotor activity, 421
neuroleptics, 661
reinforcement, 661
Halothane, 797
ethanol
operant behavior
solvents
toluene
Hamsters
locomotor activity, 399
morphine, 157
naltrexone, 399
sensitization, 157
strain differences, 399
tolerance, 157
Handling stress, 337
colonic temperature
hyperthermia
naltrexone
HDL-lipid composition, 343
human studies
$\Delta^9$-THC
Head-dipping, 521
discrimination
pimozide
reward
self-stimulation
Head twitches, 683
electroconvulsive shock
locomotor activity
Heart rate, 973
body temperature
ethanol
tolerance
Helplessness, 531
cortex
glutamate
stress
Heroin, 175
naltrexone
self-stimulation
Heroin conditioning, 215
housing

opiate receptors
place preference
5HT receptor blockers, 5
female receptivity
5HT synthesis
lordosis
5HT receptors, 677
hallucinogens
operant behavior
pirenperone
5HT synthesis, 5
female receptivity
5HT receptor blockers
lordosis
High affinity choline uptake, 297
ethylcholine aziridinium
passive avoidance
Hippocampal pyramidal cells, 147
muscarinic receptors
passive avoidance
trimethyl tin
Hippocampus
antinociception, 1007
benzodiazepine receptor binding, 1007
caffeine, 449
hyperactivity, 449
L-PIA, 449
operant behavior, 449
triethyl lead, 1007
Hormone
aldosterone, 707
corticosterone, 357, 631, 707
estradiol benzoate, 279, 613, 689, 1019, 1025
estrogen, 967
luteinizing hormone, 233, 415, 1019
noradrenaline, 403
progesterone, 279, 1019, 1025
prolactin, 631
testosterone, 415, 1019
Housing, 215
heroin conditioning
opiate receptors
place preference
HPLC, 85
biogenic amines
catecholamine analysis
Human studies
acute intoxication, 811
alcohol, 233
alcohol metabolism, 811
body composition, 811
diet, 993
ethanol, 993
HDL-lipid composition, 343
luteinizing hormone levels, 233
menopausal women, 233
social drinking, 993
$\Delta^9$-THC, 343
urinary salsolinol, 993
6-Hydroxydopamine, 1075
aging
clonidine
denervation
locomotor activity
Hyperactivity
caffeine, 449
desipramine, 917
hippocampus, 449
hypoactivity, 917
L-PIA, 449
operant behavior, 449
locomotor activity, 917
Hyperphagia, 753
CGS 9896
clonazepam
eating
Ro5-3663
Ro5-4864
Ro15-1788
Hyperprolinemia, 1053
aminoaciduria
learning deficits
proline
Hyperthermia
colonic temperature, 337
handling stress, 337
hypothermia, 489
naltrexone, 337
serotonergic agents, 489
wet dog shakes, 489
Hypertonic saline, 493
drinking
ethanol
thirst
Hypoactivity
desipramine, 917
hyperactivity, 917
hyperthermia, 489
locomotor activity, 917
serotonergic agents, 489
wet dog shakes, 489
Hypothyroid, 605
locomotion
perinatal exposure
perseveration
spatial maze

In vitro, 317
isolated perfused mouse brain
neuropeptide secretion
nicotine
pituitary
Initial sensitivity, 19
dependence
ethanol consumption
Intestinal enzyme activity, 589
exocrine pancreas
linear growth
obesity
synthetic diets
Intracranial drug administration, 57
amphetamine
anorexia
desmethylimipramine
Investigatory behavior, 803
locomotor activity
opioid systems
stress
Isolated perfused mouse brain, 317
in vitro
neuropeptide secretion
nicotine
pituitary

Juvenile rats, 421
caffeine
2-chloroadenosine
drug interaction
haloperidol
locomotor activity

Ketamine, 653
locomotion
open field
Kindling, 421
cocaine
prepyriform cortex
Lead exposure, 107
activity
stress
Learned tolerance, 293
ethanol
tail flick
Learning
age differences, 301
cyclic AMP, 183
memory, 301
radial maze performance, 301
spatial discrimination task, 301
vasopressin, 183
Learning deficits, 1053
aminoaciduria
hyperprolinemia
proline
Lesions, cortical, 1001
amphetamine
DRL-20
supersensitivity
Lesions, 6-hydroxydopamine, 547
apomorphine
denervation supersensitivity
Lesions, midbrain raphe, 559
lithium
muricide
prophylactic effects
olfactory bulbectomy
rubidium
Lethality, 333
opioid-antihistamine interactions
Lick duration, 541
neuroleptics
operant licking
Linear growth, 589
exocrine pancreas
intestinal enzyme activity
obesity
synthetic diets
Lithium
amitriptyline, 119
aversion, 695
avoidance, 695
energy balance, 119
exploration, 695
glucoregulation, 119
lesions, midbrain raphe, 559
mianserin, 119
muricide, 559
position learning, 695
olfactory bulbectomy, 559
prophylactic effects, 559
rubidium, 559
Locomotor activity
aging, 461, 1075
aniracetam, 645
anorexia, 671
avoidance, 645
anxiety, 941
behavioral inhibition, 25
caffeine, 421
$\beta$-carbolines, 941
caudate nucleus, 159
chlordiazepoxide, 665
2-chloroadenosine, 421
clonidine, 1075
cyclazocine, 671
denervation, 1075
desipramine, 917
diazepam, 25
DL-erythro-DOPS, 979
DL-threo-DOPS, 979
dopamine, 461, 599
dopamine-$\beta$-hydroxylase inhibitors, 535

dopamine receptors, 341
drug interaction, 421
eating, 535, 671
electroconvulsive shock, 683
emotional responsiveness, 665
enkephalin, 599
ethanol, 1013
exploration, 941
FG 7142, 941
haloperidol, 421
hamsters, 399
head twitches, 683
6-hydroxydopamine, 1075
hyperactivity, 917
hypoactivity, 917
hypothyroid, 605
investigatory behavior, 803
juvenile rats, 421
ketamine, 653
monoamine content, 1013
motility, 599
naltrexone, 399
neurotensin, 189
nialamide, 461
nicotine, 461
norepinephrine, 535
open field, 653
opioid system, 803
perinatal exposure, 605
perseveration, 605
β-phenylethylamine, 159
piracetam, 645
plasma concentrations, 941
prostaglandin $D_2$, 365
quipazine, 671
rearing, 341
sedation, 189, 365
serotonergic system, 365
social interaction, 941
spatial maze, 605
strain differences, 399
stress, 665, 803
thyrotropin-releasing hormone, 1013
tolerance, 189

Lordosis
adrenergic stimulation, 613
alpha adrenergic antagonists, 279
beta adrenergic antagonists, 279
drug interaction, 613
female receptivity, 5
5HT receptor blockers, 5
5HT synthesis, 5
molecular regulation, 613
proceptivity, 1025
progesterone, 279
serotonin, 1025
sexual behavior, female rat, 1025

L-PIA, 449
caffeine
hippocampus
hyperactivity
operant behavior

LSD, 41
classical conditioning
morphine
nictitating membrane response
rabbits

Luteinizing hormone levels, 233
alcohol
human studies
menopausal

Luteinizing hormone releasing hormone, 967
proceptive behavior
sexual preference
sexual receptivity

Matching-to-sample, 745
aniracetam
monkeys
pigeons
short-term monkeys

Maternal opiate exposure, 949
methadone
perinatal biochemistry
self-administration

Memory
age differences, 301
amnesia, 377
atropine, 243
brain serotonin, 377
caudate nucleus, 243
learning, 301
passive avoidance, 243
radial maze performance, 301
striatal cholinergic activity, 243

Menopausal women, 233
alcohol
human studies
luteinizing hormone levels

Methamphetamine
cathinone, 913
cocaine, 913
dopamine depletion, 737
drug discrimination, 913
rhesus monkeys, 737
stimulus properties, 913
supersensitivity, 737
tolerance, 737

Method
film autoradiography, 699
high performance liquid chromatography, 85
hot plate testing, 1007
radiohistochemistry, 859
single unit electrophysiological recordings, 875

Methadone, 949
maternal opiate exposure
perinatal biochemistry
self-administration

Methylxanthines
adenosine receptors, 195
antinociception, 905
baclofen, 905
caffeine, 195
clonidine, 905
dopamine antagonists, 905
drug discrimination, 815
operant behavior, 815
phosphodiesterase inhibitor, 815
taste, 195

Methysergide, 885
play
quipazine
serotonin

Mianserin, 119
amitriptyline
energy balance
glucoregulations
lithium

Molecular regulation, 613
adrenergic stimulation
drug interaction
lordosis

Monkeys
acquisition, 1061
aggression, 135
d-amphetamine, 135
aniracetam, 745
concurrent fixed ratio schedule, 61
drug interaction, 1061
matching-to-sample, 745
nicotine, 61
opioids, 1061
pigeons, 745
self administration, 61
short-term memory, 745
social interaction, 135

Monoamine content, 1013
ethanol
locomotor activity
thyrotropin-releasing hormone

Monoamines, 153
depletion
phenol-induced tremor

Morphine
amphetamine, 101
classical conditioning, 41
clonidine, 573
cross-tolerance, 573
dependence, 921, 933
dorsal immobility response, 505
fixed ratio schedules, 573
hamsters, 157
indomethacin, 921
LSD, 41
naloxone, 361, 505
neuroleptics, 101
nictitating membrane response, 41
operant behavior, 921, 933
place conditioning, 101
prenatal exposure, 227
prostaglandins, 921, 933
reproduction, 227
reward, 101
sensitization, 157
sexual behavior, rats, 361
steroid receptors, 227
tolerance, 157, 921
tonic immobility, 505

Morphine analgesia, 395
drug interaction
pentobarbital
potentiation

Morphine, intrathecal, 271
place conditioning
tail flick

Motility
conditioned suppression, 249
dopamine, 599
electric footshock, 249
enkephalin, 599
locomotor activity, 599
opioid activity, 249
pain-threshold, 249

Motor activity
behavioral development, 441
cholinesterase, 479
extrapyramidal system, 479
naltrexone, 441
opiate antagonists, 441
stereotypy, 479

Motor deficits, 761
neuroleptics
operant behavior
reinforcement

Mouthing, 265
ontogeny
serotonergic syndrome

Muricide, 559
lesions, midbrain raphe
lithium
prophylactic effects
olfactory bulbectomy
rubidium

Muscarinic receptors
chronic drug treatment, 283
hippocampal pyramidal cells, 147
nicotine, 283
oxotremorine, 283
passive avoidance, 147
tolerance, 283
trimethyl tin, 147

Naloxone
dorsal immobility response, 505
endogenous opiates, 91
endorphins, 791
ethanol, 91
morphine, 361, 505
operant feeding, 37
opiate abstinence syndrome, 791
opiate antagonists, 791
pigs, 37
self-administration, 91
sexual behavior, rats, 361
tonic immobility, 505
Naltrexone
analgesia, 769
behavioral development, 441
cold water swim, 769
colonic temperature, 337
hamsters, 399
handling stress, 337
heroin, 175
locomotor activity, 399
motor activity, 441
opiate antagonists, 441
self-stimulation, 175
strain differences, 399
stress, 769
tolerance, 769
Neonatal exposure, 1019
castration effects
drug injection
pituitary function
Neuroleptics
amphetamine, 101
anhedonia, 787
extinction, 661
haloperidol, 661
lick duration, 541
morphine, 101
motor deficits, 761
operant behavior, 761
operant licking, 541
pimozide, 787
place conditioning, 101
reinforcement, 661, 761
reward, 101, 787
sham feeding, 787
Neuropeptide secretion, 317
in vitro
isolated perfused mouse brain
nicotine
pituitary
Neuropharmacology, 875
adrenoceptors
electrophysiology
single unit studies
Neurotensin
locomotor activity, 189
neurotransmitters, 509
sedation, 189
stress ulcers, 509
tolerance, 189
Neurotransmitters, 509
neurotensin
stress ulcers

Nialamide, 461
aging
dopamine
locomotor activity
Nicotine
antihistamines, 469
chronic drug treatment, 283
concurrent, 61
conditioned place preference, 237
drug interactions, 469
drug toxicity, 469
fixed ratio schedule, 61
isolated perfused mouse brain, 317
locomotor activity, 897
monkeys, 61
muscarinic receptors, 283
neuropeptide secretion, 317
oxotremorine, 283
pentylenetetrazole, 469
pituitary, 317
self administration, 61
tolerance, 283
Nictitating membrane response, 41
classical conditioning
LSD
morphine
rabbits
Norepinephrine
conditioned preference, 1045
dopamine-$\beta$-hydroxylase inhibitors, 535
eating, 535, 1045
locomotor activity, 535
quinine aversion, 1045
saccharin preference, 1045
Norepinephrine uptake, 261
antidepressants
conditioned avoidance

Obesity, 589
exocrine pancreas
intestinal enzyme activity
linear growth
synthetic diets
Obsessive-compulsive neurosis, 347
trazodone
Olfactory bulbectomy
discrimination avoidance, 717
lesions, midbrain raphe, 559
lithium, 559
muricide, 559
prophylactic effects, 559
psychotropic drugs, 717
rubidium, 559
Ontogeny, 265
mouthing
serotonergic syndrome
Open field, 653
ketamine
locomotion
Operant behavior
bombesin, 893
caffeine, 449
cholecystokinin, 893
dependence, 921, 933
drug discrimination, 815
ethanol, 797
hallucinogens, 677
halothane, 797
hippocampus, 449
5HT receptors, 677
hyperactivity, 449
indomethacin, 921
lick duration, 541
L-PIA, 449
methylxanthine, 815
morphine, 921, 933
motor deficits, 761
naloxone, 37
neuroleptics, 541, 761
phosphodiesterase inhibitor, 815
pigs, 37
pirenperone, 677
prostaglandins, 921, 933
reinforcement, 761
satiety, 893
solvents, 797
tolerance, 921
toluene, 797
Opiate abstinence syndrome, 791
endorphins
naloxone
opiate antagonists
Opiate antagonism, 1035
parturition
placentophagia
tolerance
Opiate antagonists
behavioral development, 441
endorphins, 791
motor activity, 441
naloxone, 791
naltrexone, 441
opiate abstinence syndrome, 791
Opiate-ethanol interaction, 255
conditioned taste aversion
receptor stereospecificity
Opiate receptors, 215
housing
heroin conditioning
place preference
Opiates, 209
apomorphine
drug interaction
pigeons
Opioid activity, 249
conditioned suppression
electric footshock
motility
pain-threshold
Opioid-antihistamine interactions, 333
lethality
Opioid systems, 803
investigatory behavior
locomotor activity
stress
Opioids, 1061
acquisition
drug interaction
monkeys
Ovariectomy, 689
dopamine
estrogen
postural deviation
Oxotremorine, 283
chronic drug treatment
muscarinic receptors
nicotine
tolerance

Pain modulation, 845
analgesia
spinal adrenergic receptors
spinopetal pathways
Pain-threshold, 249
conditioned suppression
electric footshock

motility
opioid activity
Parturition, 1035
opiate antagonism
placentophagia
tolerance
Passive avoidance
atropine, 243
caudate nucleus, 243
ethylcholine aziridinium, 297
high affinity choline uptake, 297
hippocampal pyramidal cells, 147
memory, 243
muscarinic receptors, 147
retention, 243
striatal cholinergic activity, 243
trimethyl tin, 147
Penile erections, 31
dopaminergic pathways
yawning
Pentobarbital
anticonvulsants, 141
avoidance, 435
drug interaction, 395
freezing behavior, 435
GABAergic mechanisms, 141
morphine analgesia, 395
potentiation, 395
seizures, maximal electroshock induced, 141
strain differences, 435
Pentylenetetrazol
antihistamines, 469
audiogenic seizures, 635
betaine, 635
drug interactions, 469
drug toxicity, 469
nicotine, 469
seizures, 635
Pentylenetetrazol seizures, 515
cyclazocine
rabbits
Peptide
ACTH, 317
angiotensin II, 553
bombesin, 893
p-chlorophenylalanine, 153
cholecystokinin, 893
β-endorphin, 317
enkephalin, 599
follicle stimulating hormone, 1019
gonadotropin, 1019
6-hydroxydopamine, 153
LHRH, 967
α-methyl-p-tyrosine, 153
αMSH, 317
neurotensin, 189, 509
thyrotropin-releasing hormone, 1013
vasopressin, 183
xenopsin, 189
Perinatal biochemistry, 949
maternal opiate exposure
methadone
self-administration
Perinatal exposure, 605
hypothyroid
locomotion
perseveration
spatial maze
Perseveration, 605
hypothyroid
locomotion
perinatal exposure
spatial maze
Phencyclidine, 731
dopamine uptake
$^3$H-phencyclidine
turning behavior
$^3$H-Phencyclidine binding, 731
dopamine uptake
phencyclidine
turning behavior
Phenethylamine, 497
excretion
stress
Phenobarbital, 389
fixed-ratio schedule
phenytoin
valproic acid, 389
Phenol-induced tremor, 153
depletion
monoamine
Phentermine, 1071
body weight
food delivery schedule
food deprivation
self-administration
β-Phenylethylamine, 159
caudate nucleus
locomotor activity
Phenylisopropylamines, 723
CNS stimulants
drug discrimination
hallucinogens
structure-activity studies
dl-Phenylpropanolamine, 781
brown adipose tissue
caffeine
drug synergism
thermogenesis
Phenytoin
anticonvulsants, 53
drug interactions, 53
eboracin, 53
fixed-ratio schedule, 389
phenobarbital, 389
valproic acid, 389
Phosphodiesterase inhibitor, 815
drug discrimination
methylxanthine
operant behavior
Pigeons
aniracetam, 745
apomorphine, 209
drug interaction, 209
matching-to-sample, 745
monkeys, 745
opiates, 209
short-term memory, 745
Pigs, 37
naloxone
operant feeding
Pimozide
anhedonia, 787
discrimination, 521
head-dipping, 521
neuroleptics, 787
reward, 521, 787
self-stimulation, 521
sham feeding, 787
Piracetam, 645
aniracetam
avoidance
locomotor activity
Pirenperone
hallucinogens, 677
5HT receptors, 677
operant behavior, 677
quipazine, 565
serotonin, 565
sexual behavior, male rat, 565
Pituitary
cyclic AMP, 631
habituation, 631
isolated perfused mouse brain, 317
neuropeptide secretion, 317
nicotine, 317
stress, 631
Pituitary function, 1019
castration effects
drug interactions
neonatal exposure
Place conditioning
amphetamine, 101
morphine, 101
morphine, intrathecal, 271
neuroleptics, 101
reward, 101
tail flick, 271
Place preference, 215
heroin conditioning
housing
opiate receptors
Placentophagia, 1035
opiate antagonism
parturition
tolerance
Plasma concentrations, 941
anxiety
β-carbolines
exploration
FG 7142
locomotor activity
social interaction
Play, 885
methysergide
quipazine
serotonin
Position learning, 695
aversion
avoidance
exploration
lithium
Postural deviation, 689
dopamine
estrogen
ovariectomy
Potentiation, 395
drug interaction
morphine analgesia
pentobarbital
3-PPP, 309
dopamine agonists
dopamine antagonists
self-stimulation
[$^3$H]Prazosin, 859
α-adrenergic receptors
[$^3$H]WB4101
receptor autoradiography
Prenatal exposure, 227
morphine
reproduction
steroid receptors
Prepyriform cortex, 421
cocaine
kindling
Proceptive behavior, 967
luteinizing hormone releasing hormone
sexual preference
sexual receptivity
Proceptivity, 1025
lordosis

serotonin
sexual behavior, female rat
Progesterone, 279
alpha adrenergic antagonists
beta adrenergic antagonists
lordosis
Proline, 1053
hyperprolinemia
learning deficits
Prophylactic effects, 559
lesions, midbrain raphe
lithium
muricide
olfactory bulbectomy
rubidium
Prostaglandin $D_2$
locomotor activity, 365
sedation, 365
serotonergic system, 365, 371
synaptosomes, 371
Prostaglandins
dependence, 921, 933
indomethacin, 921
morphine, 921, 933
operant behavior, 921, 933
tolerance, 921
Psychotropic drugs
antidepressants, 71
benzodiazepine antagonists, 71
discrimination avoidance, 717
olfactory bulbectomy, 717
shuttlebox, 71

Quinine aversion, 1045
conditioned preference
eating
norepinephrine
saccharin preference
Quipazine
anorexia, 671
cyclazocine, 671
eating, 671
locomotor activity, 671
methysergide, 885
pirenperone, 565
play, 885
serotonin, 565, 885
sexual behavior, male rat, 565

Rabbits
appetite, 649
classical conditioning, 41
clonidine, 649
cyclazocine, 515
eating, 649
LSD, 41
morphine, 41
nictitating membrane response, 41
pentylenetetrazol seizures, 515
stereospecific opiate antagonism, 649
Radial maze performance, 301
age difference
learning
memory
spatial discrimination task
Rapid eye movement, 889
brain serotonin
*p*-chloroamphetamine
respiratory rate
Rearing, 341
dopamine receptors
locomotor activity
Receptor autoradiography, 859
$\alpha$-adrenergic receptors
[$^3$H]prazosin
[$^3$H]WB4101
Receptor ontogeny, 985
benzodiazepine receptors
cerebellum
cortex
Receptor stereospecificity, 255
conditioned taste aversion
opiate-ethanol interaction
Receptor subtypes, 835
alpha-2 adrenergic receptors
strain differences
Reinforcement
extinction, 661
haloperidol, 661
motor deficits, 761
neuroleptics, 661, 761
operant behavior, 761
Reproduction, 227
morphine
prenatal exposure
steroid receptors
Respiratory depression, 221
serotonin agonists
serotonin turnover
Respiratory rate, 889
brain serotonin
*p*-chloroamphetamine
rapid eye movement
Retention, 243
atropine
caudate nucleus
passive avoidance
memory
striatal cholinergic activity
Reward
amphetamine, 101
anhedonia, 787
discrimination, 521
head-dipping, 521
morphine, 101
neuroleptics, 101, 787
pimozide, 521, 787
place conditioning, 101
self-stimulation, 521
sham feeding, 787
Rhesus monkeys, 737
dopamine depletion
methamphetamine
supersensitivity
tolerance
Ro5-3663, 753
CGS 9896
clonazepam
eating
hyperphagia
Ro5-4864
Ro15-1788
Ro5-4864, 753
CGS 9896
clonazepam
eating
hyperphagia
Ro5-3663
Ro15-1788
Ro15-1788, 753
CGS 9896
clonazepam
eating
hyperphagia
Ro5-3663
Ro5-4864
Rotational behavior, 901
cocaine
sensitization
tolerance
Rubidium, 559
lesions, midbrain raphe
lithium
muricide
prophylactic effects
olfactory bulbectomy

Saccharin preference, 1045
conditioned preference
eating
norepinephrine
quinine aversion
Sarcosine, 641
betaine
dimethylglycine
seizures
strychnine
Satiety, 893
bombesin
cholecystokinin
operant responding
Sedation
antihistamines, 15
locomotor activity, 189, 365
neurotensin, 189
prostaglandin $D_2$, 365
serotonergic system, 365
stimulus control, 15
tolerance, 189
Seizures
audiogenic seizures, 635
betaine, 635, 641
dimethylglycine, 641
pentylenetetrazol, 635
sarcosine, 641
strychnine, 641
Seizures, maximal electroshock induced, 141
anticonvulsants
GABAergic mechanisms
pentobarbital
Self-administration
body weight, 1071
cocaine, 945
concurrent fixed ratio schedule, 61
conditioned taste aversion, 945
dopamine, 945
endogenous opiates, 91
ethanol, 91
food delivery schedule, 1071
food deprivation, 1071
maternal opiate exposure, 949
methadone, 949
monkeys, 61
naloxone, 91
nicotine, 61
perinatal biochemistry, 949
phentermine, 1071
Self-stimulation
discrimination, 521
dopamine agonists, 309
dopamine antagonists, 309
head-dipping, 521
heroin, 175
naltrexone, 175
pimozide, 521
3-PPP, 309
reward, 521

Self-stimulation thresholds, 527
brain stimulation reward
Sensitization
cocaine, 901
hamsters, 157
morphine, 157
rotational behavior, 901
tolerance, 157, 901
Serotonergic agents, 489
hyperthermia
hypothermia
wet dog shakes
Serotonergic syndrome, 265
mouthing
ontogeny
Serotonergic system
locomotor activity, 365
prostaglandin $D_2$, 365, 371
sedation, 365
synaptosomes, 371
Serotonin
ethanol, voluntary intake, 205
lordosis, 1035
methysergide, 885
pirenperone, 565
play, 885
proceptivity, 1025
quipazine, 565, 885
sexual behavior, female rat, 1025
sexual behavior, male rat, 565
striatum, 205
Serotonin agonists, 221
respiratory depression
serotonin turnover
Serotonin concentrations, 327
asymmetry
spontaneous activity
Serotonin turnover, 221
respiratory depression
serotonin agonists
Sexual behavior, female rat, 1025
lordosis
proceptivity
serotonin
Sexual behavior, male mice, 415
genetics
$\Delta^9$-tetrahydrocannabinol
Sexual behavior, male rats
copulation, 1
fluprazine, 1
pirenperone, 565
quipazine, 565
serotonin, 565
Sexual behavior, rats, 361
morphine
naloxone
Sexual preference, 967
luteinizing hormone releasing hormone
proceptive behavior
sexual receptivity
Sexual receptivity, 967
luteinizing hormone releasing hormone
proceptive behavior
sexual preference
Sham feeding, 787
anhedonia
neuroleptics
pimozide
reward
Short-term memory, 745
aniracetam
matching-to-sample
monkeys
pigeons
Shuttlebox, 71
antidepressants
benzodiazepine antagonists
psychotropic drugs
Single unit studies, 875
adrenoceptors
electrophysiology
neuropharmacology
Skeletal growth, 707
aldosterone
body fat
body water
Social drinking, 993
diet
ethanol
human studies
urinary salsolinol
Social interaction
aggression, 135
d-amphetamine, 135
anxiety, 941
$\beta$-carbolines, 941
exploration, 941
FG 7142
locomotor activity, 941
monkeys, 135
plasma concentrations, 941
Social play, 881
clonidine
yohimbine
Sodium transport, 955
barbiturates
dependence
tolerance
Solvents, 797
ethanol
halothane
operant behavior
toluene
Soman, acetylcholinesterase, 961
baboons
discrimination
Spatial discrimination task, 301
age difference
learning
memory
radial maze performance
Spatial maze, 605
hypothyroid
locomotion
perinatal exposure
perseveration
Spinal adrenergic receptors, 845
analgesia
pain modulation
spinopetal pathways
Spinopetal pathways, 845
analgesia
pain modulation
spinal adrenergic receptors
Spontaneous activity, 327
asymmetry
serotonin concentrations
Stereospecific opiate antagonism, 649
appetite
clonidine
eating
rabbits
Stereotypy, 479
cholinesterase
extrapyramidal system
motor activity
Steroid receptors, 227
morphine
prenatal exposure
reproduction
Stimulus control, 15
antihistamines
sedation
Stimulus properties, 913
cathinone
cocaine
drug discrimination
methamphetamine
Strain differences
alpha-2 adrenergic receptors, 835
avoidance, 435
body temperature, 623
brain AChE activity, 623
diisopropylfluorophosphate, 623
freezing behavior, 435
hamsters, 399
locomotor activity, 399
naltrexone, 399
pentobarbital, 435
receptor subtypes, 835
Stress
activity, 107
analgesia, 769
chlordiazepoxide, 665
cold water swim, 769
cortex, 531
cyclic AMP, 631
emotional responsiveness, 665
excretion, 497
glutamate, 531
habituation, 631
helplessness, 531
investigatory behavior, 803
lead exposure, 107
locomotor activity, 665, 803
naltrexone, 769
opioid systems, 803
phenethylamine, 497
pituitary, 631
tolerance, 769
Stress ulcers, 509
neurotensin
neurotransmitters
Striatal cholinergic activity, 243
atropine
caudate nucleus
passive avoidance
memory
retention
Striatum, 205
ethanol, voluntary intake
serotonin
Structure-activity studies, 723
CNS stimulants
drug discrimination
hallucinogens
phenylisopropylamines
Strychnine, 641
betaine
dimethylglycine
sarcosine
seizures
Supersensitivity
amphetamine, 1001
dopamine depletion, 737
DRL-20, 1001
lesions, cortical, 1001
methamphetamine, 737
rhesus monkeys, 737
tolerance, 737
Synaptosomes, 371
prostaglandin $D_2$
serotonergic system

Synthetic diets, 589
exocrine pancreas
intestinal enzyme activity
linear growth
obesity

Tail flicks
ethanol, 293
learned tolerance, 293
morphine, intrathecal, 271
place conditioning, 271
Taste, 195
adenosine receptors
caffeine
methyl xanthines
Taste preference, 699
appetite
drinking
eating
film autoradiography
gustatory neuroanatomy
$\Delta^9$-Tetrahydrocannabinol, 415
genetics
sexual behavior, male mice
Thermogenesis, 781
brown adipose tissue
caffeine
drug synergism
dl-phenylpropanolamine
$\Delta^9$-THC, 343
HDL-lipid composition
human studies
5-Thioglucose, 407
alloxan
2-deoxy-D-glucose
glucoprivic feeding
Thirst
$\beta$-adrenergic antagonists, 553
drinking, 493, 553
ethanol, 493
hypertonic saline, 493
water deprivation, 553
Thyrotropin-releasing hormone, 1013
ethanol
locomotor activity
monoamine content
Tolerance
analgesia, 769
barbiturates, 955
body temperature, 973
chronic drug treatment, 283
cocaine, 901
cold water swim, 769
dependence, 921, 955
dopamine depletion, 737
ethanol, 973
ethanol, acute, 77
ethanol, chronic, 77
GABA mediated mechanisms, 77
hamsters, 157
heart rate, 973
indomethacin, 921
locomotor activity, 189
methamphetamine, 737
morphine, 157, 921
muscarinic receptors, 283
naltrexone, 769
neurotensin, 189
nicotine, 283
operant behavior, 921
opiate antagonism, 1035
oxotremorine, 283
parturition, 1035
placentophagia, 1035
prostaglandins, 921
rhesus monkeys, 737
rotational behavior, 901
sedation, 189
sensitization, 157, 901
sodium transport, 955
stress, 769
supersensitivity, 737
Toluene
baboons, 583
discrimination, 583
ethanol, 583, 797
halothane, 797
operant behavior, 797
solvents, 797
Tonic immobility, 505
dorsal immobility response
morphine
naloxone
Trazedone, 347
obsessive-compulsive neurosis
Triethyl lead, 1007
antinociception
benzodiazepine receptor binding
hippocampus
Trimethyl tin, 147
hippocampal pyramidal cells
muscarinic receptors
passive avoidance
Turning behavior, 731
dopamine uptake
phencyclidine
$^3$H-phencyclidine binding

Urinary salsolinol, 993
diet
ethanol
human studies
social drinking

Valproic acid, 389
fixed-ratio schedule
phenobarbital
phenytoin
Vasopressin, 183
cyclic AMP
learning

Water deprivation, 553
$\beta$-adrenergic antagonists
drinking
thirst
[$^3$H]WB4101, 859
$\alpha$-adrenergic receptors
[$^3$H]prazosin
receptor autoradiography
Wet dog shakes, 489
hyperthermia
hypothermia
serotonergic agents

Yawning, 31
dopaminergic pathways
penile erections
Yohimbine, 881
clonidine
social play

# AUTHOR INDEX


Abe, Y., 559
Adams, M. A., 993
Advokat, C., 271
Agmo, A., 599
Alexander, G. J., 53
Alexander, R. B., 53
Allen, M. C., 509
Amit, Z., 215, 255, 945
Ando, K., 737
Anisman, H., 521
Araki, H., 559
Arnsten, A. F. T., 803
Asin, K. E., 169, 661
Atrens, D. M., 119
Avery, D. D., 893

Babcock, A. M., 893
Baldwin, B. A., 37
Baldwin, R. A., 1053
Balster, R. L., 61, 797
Barfield, R. J., 227
Barney, C. C., 553
Barrett, J., 107
Bartke, A., 415, 1019
Baum, M. J., 361
Bavli, S., 233
Baxter, C. F., 1053
Beaman, C. M., 483
Becker, J. B., 901
Beninger, R. J., 341, 535
Berge, O.-G., 293
Bernardis, L. L., 589
Bernstein, D., 301
Berridge, C., 803
Beyer, C., 279, 613
Black, R. S., 327
Blanchard, D. C., 1
Blanchard, R. J., 1
Boismare, F., 205
Bondy, S. C., 1007
Booth, D. A., 57, 1045
Borrell, S., 357
Bowers, W., 521
Brady, J. V., 1001
Braestrup, C., 941
Breese, G. R., 221, 1013
Broekkamp, C. L. E., 309
Broitman, S. T., 917
Brooks, S., 589
Bryson, R., 897
Bylund, D. B., 835
Byrd, L. D., 135

Carlisle, H. J., 761
Chretien, P., 205
Clody, D. E., 147
Collins, A. C., 283, 623
Comer, C. P., 605
Conrad, J., 897
Cooper, S. J., 25, 753
Cornell, K., 317
Coupet, J., 147
Cousin, K. M., 461
Coyle, S., 1013
Cronan, T., 897
Cunningham, C. L., 973
Curtis, A. L., 825

Dalterio, S., 1019
Dar, M. S., 77
Daoust, M., 205
Davis, J. L., 1053
Dean, R. L., 147
de Avila, N., 599
DeMesquita, S., 889
Devenport, L. D., 707
Deviche, P., 209
Diamond, M., 1
Diamond, P., 361
Diaz, C., 195
Dionyssiou-Asteriou, A., 343
Dourish, C. T., 159
Doyle, T. F., 91
Driscoll, P., 435
Driver, G. C., 631
Dudley, C. A., 967

Echandía, E. L. R., 917
Eggleston, T., 631
Eguíbar, J. R., 31
Eikelboom, R., 535
Eisenhofer, G., 493
Ellingboe, J., 233
Ellison, F., 215
Englert, L. F., 297
Erwin, V. G., 317
Etgen, A. M., 227
Ettenberg, A., 761
Evans, D. R., 993
Evans, H. L., 745
Evans, K. R., 535

Faris, P. L., 1035
Fernandez, I., 859
Fernández-Guasti, A., 279, 613
Fernández-Samblancat, M., 243
File, S. E., 941
Flood, J. F., 1053
Forler, C., 547
Fóscolo, M. R., 917
Fowler, S. C., 541
Flannelly, K. J., 1
Frank, R. A., 527
Freed, W. J., 635, 641
Freeman, G. B., 665
Freeman, K., 791
Frye, G. D., 1013
Fudala, P. J., 237
Furukawa, T., 645

Gallus, J. A., 333
Garrett, K. M., 985
Gause, E. M., 583, 961
Geary, N., 787
Geller, I., 583, 961
Gerald, M. C., 461
Gerhardt, S., 71
Ghoz, E. H., 635
Gibson, E. L., 1045
Gilbert, D. B., 753
Gill, J. M., 195
Girardot, M.-N., 769
Gleeson, R. M., 119
Glennon, R. A., 723, 913
Goist, K. C., Jr., 811
Goldberg, L. I., 577
Goldblum, N., 361
Gomita, Y., 717
Goodwin, K. G., 707
Gormezano, I., 41
Gorzalka, B. B., 565, 1025
Gowdey, C. W., 993
Gower, A. J., 309
Gramling, S. E., 541
Guaza, C., 357
Gudelsky, G. A., 489

Haines, R. J., 961
Hall, C. E., 619
Hamburger-Bar, R., 183
Hamilton, M., 521
Harmon, R. E., 469
Harris, R. A., 955
Hartmann, R. J., 583, 961
Harvey, J. A., 41
Hashimoto, H., 979
Hauck, A. E., 723
Heckathorn, D., 497
Heffner, T., 85
Henck, J. W., 671
Hernandez, D. E., 509
Hetzler, B. E., 653
Heyward, P., 493
Higson, F. M., 119
Hines, G., 695
Hirst, M., 993
Ho, B. T., 297
Hoffman, D. C., 341
Höglund, A. U., 403
Hole, D. R., 5
Hole, K., 293
Hollingsworth, E. B., 365, 371
Holloway, F. A., 449, 769, 815
Holloway, W. R., Jr., 421
Holmgren, B., 31
Hong, J. S., 1007
Hopkins, P. M., 707
Horita, A., 337
Hovious, J. R., 949
Hubbell, C. L., 483
Hungerford, S., 619
Hunsinger, R. N., 127
Hunt, T., 215, 945
Hunter, A. J., 5
Hunter, G. A., 483

Ingram, D. K., 301
Inoue, T., 645
Iser, C., 361
Iwamoto, E. T., 237

Johanson, C. E., 737
Johnson, K. M., 731
Jørgensen, H. A., 293
Kalofoutis, A., 343
Kameyama, T., 249
Kamien, J. B., 577
Kant, G. J., 631
Kato, N., 979
Katovich, M. J., 553
Katz, N. L., 649
Kenion, C. C., 631
Kennedy, J., 469
Kinzler, W. C., 791
Kisara, K., 153
Koch, C., 389
Koenig, J. I., 489
Komisaruk, B. R., 1035
Kopeloff, L. M., 53
Kotake, C., 85
Koutselinis, 343
Krall, S., 699
Kramer, G., 531
Kubos, K. L., 1001

Lai, H., 337
Lalonde, R., 377
Landman-Roberts, L., 631
Larsson, K., 279, 613
Leal, B. Z., 961
Leavell, J. G., 791
Lebenthal, E., 589
Lee, P. C., 589
Le Magnen, J., 19
Lhuintre, J. P., 205
Lieblich, I., 361
Liebman, J. M., 71
Lim, H. L., 1
Lin-Chu, 901
Lints, C. E., 711
Lippa, A. S., 147
Livesey, P. J., 107
Livosky, M., 893
London, E. D., 301
Loullis, C. C., 147
Lowy, M. T., 399
Lucki, I., 261
Lynch, W. C., 699

McChesney, C., 531
McKearney, J. W., 573
McLaughlin, P. J., 441
McMaster, S. B., 479

Mackey, W. B., 101
Malin, D. H., 791
Maravelias, C., 343
Marfaing-Jallat, P., 19
Marks, M. J., 283
Marmon, M. M., 781
Marty, M. A., 317
Marwaha, J., 875
Matthews, J. W., 1045
Mayer, A. D., 1035
Mayfield, D., 1019
Meisenberg, G., 189
Mello, N. K., 233
Meltzer, H. Y., 489
Mendelson, J. H., 233

Mendelson, S. D., 565, 1025
Mendez, V., 583
Meyer, M. E., 505
Meyerhoff, J. L., 631
Meyerson, B. J., 403
Michaelis, R. C., 815
Misra, A. L., 395
Mitchell, M. A., 955
Modrow, H. E., 815
Moerschbaecher, J. M., 1061
Mokler, D. J., 677
Moore, N., 205
Moran, E., 961
Moran, T. H., 1001
Mori, T., 979
Moser, V. C., 797
Moss, D. E., 479
Moss, R. L., 967
Mueller, R. A., 221, 1013
Murnane, J. M., 407

Nabeshima, T., 249
Nakajima, T., 979
Nanry, K. P., 469
Nasseth, D., 619
Nawiesniak, E., 175
Nearchou, N. I., 333
Newman, M. E., 183
Ng Cheong Ton, J. M., 255
Nielson, J. A., 921, 933
Niglio, T., 515
Nobler, M. S., 261
Normansell, L., 881, 885
Norton, S., 605
Noto, T., 979
Nyquist-Battie, C., 711

Ogawa, N., 717
Olton, D. S., 301
Orensanz, L. M., 859
Ortolani, E., 515

Paden, C. M., 699
Pae, Y.-S., 337
Palfreyman, M. G., 547
Panksepp, J., 881, 885
Papasava, C. L., 1071
Papasava, M., 1071
Pappas, B. A., 1075
Parrott, R. F., 37
Patrick, G. A., 365, 371
Pellow, S., 941
Peris, J., 955, 973
Peters, M. A., 949
Petty, F., 531
Pézzola, A., 515
Pick, C. G., 361
Picker, M., 389
Poling, A., 333, 389
Pontani, R. B., 395
Pontecorvo, M. J., 745
Pope, C. N., 297
Prado-Alcalá, R. A., 243
Prange, A. J., Jr., 509
Prasad, A., 347

Rastogi, S. K., 141
Reagan, M. A., 791
Rech, R. H., 671, 677
Reid, L. D., 483
Reynolds, M. A., 301
Rezabek, D. H., 671
Ristine, L. A., 265
Ritter, S., 407
Robin, M., 547
Robinson, R. G., 327, 1001
Robinson, T. E., 901
Rodriguez, L. A., 479
Rosenblatt, J. S., 1035
Ruffolo, R. R., Jr., 827
Russell, R. D., 421

Sagratella, S., 515
Saligut, C., 205
Samson, H. H., 91
Sangiah, S., 399
Sawynok, J., 905
Schechter, M. D., 179, 913
Schenk, S., 175, 215
Schiffman, S. S., 195
Schindler, C. W., 41
Schlemmer, R. F., Jr., 649
Schnur, P., 157
Schuster, C. R., 737
Scotti de Carolis, A., 515
Segal, D. S., 803
Seiden, L. S., 85, 737
Sewell, R. G., Jr., 333, 469
Shrenker, P., 415
Shull, R. N., 449
Simmons, W. H., 189
Singer, G., 1071
Slifer, B. L., 61
Smith, C. H., 1001
Smith, E. O., 135
Smith, G. P., 787
Smith, R. L., 505, 689
Smolen, A., 623
Smolen, T. N., 623
Smythe, G. A., 119
Smythe, J. W., 1075
Snell, L. D., 731
Snoddy, A. M., 497
Solodkin-Herrera, M., 243
Sparber, S. B., 921, 933
Spear, L. P., 265
Stanley, D. A., 509
Steardo, L., 905
Steger, R., 1019
Stiger, T. R., 469
Storlien, L. H., 119
Stoudt, K. W., 677
Stripling, J. S., 427
Stübi, R., 435
Sutker, P. B., 811
Suzuki, T., 153
Swain-Wautlet, B., 653
Switzman, L., 945

Tabakoff, B., 169, 985
Tanaka, M., 645
Teoh, K. W., 237
Tessel, R. E., 497
Thomas, J., 389
Thompson, D. M., 1061
Thor, D. H., 421
Thurmond, J. B., 665
Ticku, M. K., 141
Tilson, H. A., 1007
Towell, A., 57
Towle, A., 221
Treit, D., 47, 383
Trucios, N., 31

Ueki, S., 559, 717
Unnerstall, J. R., 859
Urbá-Holmgren, R., 31
Uretsky, N. J., 461

Vadlamani, N. L., 395
van der Kooy, D., 101
Van Hartesveldt, C., 689
Vathy, I. U., 227
Vikis-Freibergs, V., 377
Vosmer, G., 85

Waller, D. P., 649
Waller, S. B., 301
Walsh, T. J., 1007
Watt, J., 699
Wehner, J. M., 623
Wellman, P. J., 781
Wielosz, M., 683
Williams, H. P., 527
Willner, P., 57
Wilson, C. A., 5
Wilson, M. C., 127
Winsauer, P. J., 1061
Winter, J. C., 15
Wirtshafter, D., 169, 661
Wooles, W. R., 77
Woolverton, W. L., 577

Yaksh, T. L., 845
Yamada, K., 249, 645
Yamamoto, T., 559
Yim, G. K. W., 399
Young, R., 723

Zacharko, R. M., 521
Zagon, I. S., 441
Zermeño, M., 31
Zgombick, J. M., 317